# Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

> **NCT02129192** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Amlodipine 5mg capsule
- **DRUG:** T80/H12.5 mg FDC tablet
- **DRUG:** T80/A5/H12.5 mg FDC tablet

## Key facts

- **NCT ID:** NCT02129192
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129192, "Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02129192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*